← Eichor
Study identifier: NCT07512362 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

Condition: Mild Cognitive Impairment · Early Alzheimer's Disease · AD-MCI  ·  Sponsor: Bernard (Barry) Baumel

PhasePhase 2
Planned participants10
Who can joinAll sexes, 55 Years to 90 Years
Healthy volunteersNo

About this study

The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.

This description comes directly from the study's public registry record.

Talk to the study team

Maria E. Puertas  ·  (305) 243-3100  ·  mep980@miami.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Miami Department of NeurologyMiami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07512362